{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:25:47Z","timestamp":1794432347424,"version":"4.9.1"},"reference-count":104,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) is an uncommon mature B-cell lymphoma that presents a clinical spectrum ranging from indolent to aggressive disease, with challenges in disease management and prognostication. MCL is characterized by significant genomic instability, affecting various cellular processes, including cell cycle regulation, cell survival, DNA damage response and telomere maintenance, NOTCH and NF-\u03baB\/ B-cell receptor pathways, and chromatin modification. Recent molecular and next-generation sequencing studies unveiled a broad genetic diversity among the 2 molecular subsets, conventional MCL (cMCL) and leukemic nonnodal MCL (nnMCL), which may partially explain their clinical heterogeneity. Some asymptomatic and genetically stable nnMCL not requiring treatment at diagnosis may eventually progress clinically. Overall, the high proliferation of tumor cells, blastoid morphology, TP53 and\/or CDKN2A\/B inactivation, and high genetic complexity influence treatment outcome in cases treated with standard regimens. Emerging targeted and immunotherapeutic strategies are promising for refractory or relapsed cases and a few genetic and nongenetic determinants of refractoriness have been reported. This review summarizes the recent advances in MCL biology, focusing on molecular insights, prognostic markers, and novel therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011763","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:56:05Z","timestamp":1715784965000},"page":"3652-3664","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-1659","authenticated-orcid":false,"given":"Cristina","family":"L\u00f3pez","sequence":"first","affiliation":[{"name":"1Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Hematopathology Section, Pathology Department, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"3Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Madrid, Spain"},{"name":"4Departament de Fonaments Cl\u00ednics, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-0860","authenticated-orcid":false,"given":"Elisabeth","family":"Silkenstedt","sequence":"additional","affiliation":[{"name":"5Department of Medicine III, Ludwig-Maximilians-University Munich University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"5Department of Medicine III, Ludwig-Maximilians-University Munich University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-2385","authenticated-orcid":false,"given":"S\u00edlvia","family":"Be\u00e0","sequence":"additional","affiliation":[{"name":"1Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Hematopathology Section, Pathology Department, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"3Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Madrid, Spain"},{"name":"4Departament de Fonaments Cl\u00ednics, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2024072312505318300_bib1","author":"Swerdlow","year":"2017","edition":"4th ed"},{"issue":"11","key":"2024072312505318300_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024072312505318300_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 1","key":"2024072312505318300_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hematol Oncol"},{"issue":"12","key":"2024072312505318300_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024072312505318300_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma","volume":"133","author":"Mart\u00edn-Garcia","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024072312505318300_bib7","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1\u2212 mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2024072312505318300_bib8","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2019.237073","article-title":"Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma","volume":"105","author":"Fuster","year":"2020","journal-title":"Haematologica"},{"issue":"15","key":"2024072312505318300_bib9","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"issue":"11","key":"2024072312505318300_bib10","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2024072312505318300_bib11","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.4161\/cc.8.21.9993","article-title":"3\u2019UTR mediated regulation of the cyclin D1 proto-oncogene","volume":"8","author":"Deshpande","year":"2009","journal-title":"Cell Cycle"},{"issue":"45","key":"2024072312505318300_bib12","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"45","key":"2024072312505318300_bib13","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"7350","key":"2024072312505318300_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature10155","article-title":"A\u00a0function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers","volume":"474","author":"Jirawatnotai","year":"2011","journal-title":"Nature"},{"issue":"5","key":"2024072312505318300_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.humpath.2006.10.017","article-title":"Cyclin D1 and t(11;14)-positive B-cell neoplasms resembling marginal zone B-cell lymphoma: a morphological variant of mantle cell lymphoma","volume":"38","author":"Mansoor","year":"2007","journal-title":"Hum Pathol"},{"issue":"11","key":"2024072312505318300_bib16","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3109\/10428194.2016.1153085","article-title":"The t(11;14)(q13;q32)\/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia","volume":"57","author":"Schliemann","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024072312505318300_bib17","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1097\/HS9.0000000000000505","article-title":"CCND1 genomic rearrangement as a secondary event in high grade B-cell Lymphoma","volume":"5","author":"Cheng","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"2024072312505318300_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2024072312505318300_bib19","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2024072312505318300_bib20","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2009.008474","article-title":"Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt\u2019s lymphoma","volume":"94","author":"Dictor","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"2024072312505318300_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOH.0000000000000434","article-title":"SOX11, a key oncogenic factor in mantle cell lymphoma","volume":"25","author":"Beekman","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2024072312505318300_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41375-021-01389-w","article-title":"Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma","volume":"36","author":"Vilarrasa-Blasi","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2024072312505318300_bib23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queir\u00f3s","year":"2016","journal-title":"Cancer Cell"},{"issue":"20","key":"2024072312505318300_bib24","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"2024072312505318300_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.semcancer.2011.09.009","article-title":"Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells","volume":"21","author":"Agathangelidis","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2024072312505318300_bib26","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024072312505318300_bib27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular genetic characterization reveals new subsets of mantle cell lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2024072312505318300_bib28","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2024072312505318300_bib29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"2024072312505318300_bib30","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A\u00a0multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024072312505318300_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/gcc.20754","article-title":"Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma","volume":"49","author":"Espinet","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2024072312505318300_bib33","doi-asserted-by":"crossref","first-page":"e153283","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2024072312505318300_bib36","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2024072312505318300_bib43","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024072312505318300_bib32","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ajh.27044","article-title":"Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy","volume":"98","author":"Karolov\u00e1","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2024072312505318300_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024072312505318300_bib35","doi-asserted-by":"crossref","first-page":"13359","DOI":"10.1038\/s41598-020-70310-9","article-title":"Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study","volume":"10","author":"Jeong","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2024072312505318300_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"5-6","key":"2024072312505318300_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"25","key":"2024072312505318300_bib39","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"2024072312505318300_bib40","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"7647","key":"2024072312505318300_bib41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"7457","key":"2024072312505318300_bib42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"12","key":"2024072312505318300_bib44","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.MP.0000037310.82136.99","article-title":"Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features","volume":"15","author":"Hao","year":"2002","journal-title":"Mod Pathol"},{"issue":"8","key":"2024072312505318300_bib45","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/gcc.22849","article-title":"Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: a multi-institutional study","volume":"59","author":"Streich","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"2024072312505318300_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.onc.1209147","article-title":"Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma","volume":"25","author":"Gladden","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"2024072312505318300_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2024072312505318300_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.leu.2403571","article-title":"Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms","volume":"19","author":"Tort","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"2024072312505318300_bib49","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2015.41","article-title":"Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice","volume":"29","author":"Yamamoto","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2024072312505318300_bib50","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2024072312505318300_bib51","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2024072312505318300_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2024072312505318300_bib53","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2024072312505318300_bib54","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024072312505318300_bib55","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2024072312505318300_bib56","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"39","key":"2024072312505318300_bib57","doi-asserted-by":"crossref","first-page":"42362","DOI":"10.18632\/oncotarget.5705","article-title":"High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"2024072312505318300_bib58","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","article-title":"MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2024072312505318300_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024072312505318300_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2024072312505318300_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2024072312505318300_bib62","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"2024072312505318300_bib63","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024072312505318300_bib64","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjh.15519","article-title":"Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network","volume":"184","author":"Rauert-Wunderlich","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2024072312505318300_bib65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"2024072312505318300_bib66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2023-173615","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in mantle cell lymphoma from 1280 patients on clinical trials","volume":"142","author":"Sarkozy","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024072312505318300_bib67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bjh.17865","article-title":"Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation","volume":"195","author":"Riedell","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"2024072312505318300_bib68","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2024072312505318300_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2024072312505318300_bib70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the european mantle cell lymphoma network","volume":"41","author":"Hermine","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024072312505318300_bib71","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2024072312505318300_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024072312505318300_bib73","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"issue":"10020","key":"2024072312505318300_bib74","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"10121","key":"2024072312505318300_bib75","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"2024072312505318300_bib76","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill","year":"2024","journal-title":"Haematologica"},{"issue":"16","key":"2024072312505318300_bib77","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024072312505318300_bib78","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2024072312505318300_bib79","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"2024072312505318300_bib80","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2217\/fon-2022-0976","article-title":"BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma","volume":"18","author":"Eyre","year":"2022","journal-title":"Future Oncol"},{"issue":"17","key":"2024072312505318300_bib81","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non\u2013Hodgkin lymphoma treated with venetoclax in a phase i, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024072312505318300_bib82","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2024072312505318300_bib83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2024072312505318300_bib84","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"issue":"29","key":"2024072312505318300_bib85","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024072312505318300_bib86","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024072312505318300_bib87","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024072312505318300_bib88","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"14","key":"2024072312505318300_bib89","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024072312505318300_bib90","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024072312505318300_bib91","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024072312505318300_bib92","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2024072312505318300_bib93","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"2024072312505318300_bib94","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024072312505318300_bib95","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024072312505318300_bib96","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2024072312505318300_bib97","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB\u2013targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"2024072312505318300_bib98","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.3324\/haematol.2017.168930","article-title":"The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-\u03baB mutational status","volume":"102","author":"Vidal-Crespo","year":"2017","journal-title":"Haematologica"},{"issue":"15_suppl","key":"2024072312505318300_bib99","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial","volume":"34","author":"Lenz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024072312505318300_bib100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"491","key":"2024072312505318300_bib101","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"2024072312505318300_bib102","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis"},{"issue":"22","key":"2024072312505318300_bib103","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","article-title":"EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024072312505318300_bib104","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41420-022-01289-7","article-title":"CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma","volume":"8","author":"Fuhr","year":"2022","journal-title":"Cell Death Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3652\/2235676\/blooda_adv-2023-011763-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3652\/2235676\/blooda_adv-2023-011763-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T09:11:54Z","timestamp":1721725914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3652\/516112\/Biological-and-clinical-determinants-shaping"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":104,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011763","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}